Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05838287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

Study acronym: PIOHF
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 21 words
    • Site details revised
  2. Primary completion date: Apr 2028 to Aug 2029
    • Study completion date: Jan 2029 to Jan 2030
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2023 to Jul 10, 2023
    • Site details revised
    v3
  5. Start date: May 2023 to Jul 2023v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The University of Texas Health Science Center at San Antonio
122 trials monitored
See 10 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
and 2 more diseases
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. 2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.
Trial Details
NCT Number NCT05838287
Lead Sponsor The University of Texas Health Science Center at San Antonio
Conditions
(from sponsor)		 Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov